Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 30, 2007 Brian Orelli	Merck Tries to Stop the Flushing The FDA will review the pharma's new cholesterol drug. The biggest worry with getting CORDAPTIVE approved is probably not with its effectiveness, but with safety. Investors, take note.
The Motley Fool May 22, 2008 Brian Orelli	Merck Can't Achieve Anything The pharmaceutical cancels a troubled clinical trial.
The Motley Fool June 23, 2008 Brian Orelli	FDA Sets a Higher Standard for Merck Merck finally comes clean on what the FDA wants before the drug formally known as Cordaptive (MK-0524A) can be approved. From the looks of it, it's going to be a long wait for Merck.
The Motley Fool October 5, 2007 Brian Orelli	Merck's Next Blockbuster? Merck's cholesterol drug comes back from phase 2 testing with no side effects. Investors, take note.
The Motley Fool December 23, 2009 Brian Orelli	Cancer Isn't Merck's Biggest Problem There's still hope for Merck's Vytorin, but investors will have to wait.
The Motley Fool September 24, 2010 Brian Orelli	Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year.
The Motley Fool May 27, 2011 Brian Orelli	AIM-HIGH? These Drugmakers Better Duck. A government study on cholesterol drugs hurts Abbott and Merck.
The Motley Fool November 3, 2009 Brian Orelli	A Little Distracted, Are You, Merck? The FDA rejects its latest application.
The Motley Fool December 1, 2009 Robert Steyer	Merck Makes a Mark on Good Cholesterol Can't profit from fighting bad lipoproteins? Start boosting the good ones.
The Motley Fool January 15, 2008 Brian Orelli	No Enhance-ment From Zetia Merck and Schering report bad news, but how much will it affect sales? Investors, take note.
The Motley Fool February 4, 2009 Brian Orelli	The Tale of 2 Drugmakers Merck and Schering-Plough typically release earnings on the same day because they share sales of cholesterol drugs Vytorin and Zetia, but the drugmakers are far from the same.
The Motley Fool November 22, 2010 Brian Orelli	Let's Call It a Partial Victory Merck's Vytorin works better than a placebo. Unfortunately, it may be too little and too late to do anything about the sales cut that Vytorin has taken over the past few years.
The Motley Fool November 16, 2009 Brian Orelli	Abbott Puts a Nail in Merck's Coffin There's a clear winner from the American Heart Association conference.
The Motley Fool November 10, 2008 Brian Orelli	Drug Fuels an Idling Rocket Ship AstraZeneca needs another FDA approval to really take advantage of its cholesterol drug's success.
The Motley Fool January 9, 2009 Brian Orelli	Thanks for Nothing, FDA The Food and Drug Administration says there's still enough evidence that Merck and Schering-Plough's Vytorin works to warrant keeping patients on the drug.
The Motley Fool December 12, 2007 Brian Orelli	What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010.
The Motley Fool April 2, 2008 Michael P. Cecil	Irrational Exuberance for Vytorin and Zetia? Drugmakers Merck and Schering-Plough certainly hoped data from the Enhance study would enhance the value and status of their blockbuster cholesterol-fighting drugs Zetia and Vytorin -- but its results did quite the opposite.
The Motley Fool May 20, 2011 Brian Orelli	Abbott Hits a Triple Not a home run, but Trilipix will likely stay on the market.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool February 20, 2008 Brian Orelli	Abbott's Copycat Combinations Abbott's latest FDA approval is for Simcor, a combination of Niaspan -- Abbott's slow-release niacin -- and the active component of Merck's Zocor, which isn't patent-protected anymore. Investors take note.
The Motley Fool March 31, 2008 Brian Orelli	No Blood-Pumping Love for Merck and Schering From the reports coming out of the American College of Cardiology meeting, it looks like the drugmakers Merck and Schering-Plough took a beating.
The Motley Fool May 12, 2010 Brian Orelli	Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong.
The Motley Fool May 6, 2008 Brian Orelli	A Sign of the Pharma Times Merck is the latest big pharma cutting jobs to improve its bottom line.
The Motley Fool December 14, 2007 Brian Orelli	Panel Kills Merck's Hope of OTC Status An FDA advisory panel isn't convinced that Merck's cholesterol-lowering drug MEVACOR deserves OTC status.
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
BusinessWeek July 26, 2004 Amy Barrett	Hooked On The Cash From Cholesterol Cholesterol-lowering drugs are massive moneyspinners. But can big pharmaceutical companies sidestep expiring patents?
The Motley Fool February 11, 2010 Brian Orelli	A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool December 4, 2006 Michael P. Cecil	Pfizer's Cholesterol-Drug Hopes Crumble In surprising and disappointing news, the pharma's promising new drug fails clinical trials. With Pfizer shares declining because of the bad news, is now a good time to buy?
BusinessWeek November 24, 2010 Tom Randall	Merck May Have a Cholesterol Winner Merck told doctors at the American Heart Assn. annual meeting that new data showed its drug anacetrapib had reduced bad cholesterol by 40 percent while raising good cholesterol by an unprecedented 138 percent.
The Motley Fool March 27, 2008 Brian Orelli	I Heart the ACC What can investors expect from this weekend's blood-pumping American College of Cardiology scientific meeting?
The Motley Fool January 11, 2011 Brian Orelli	A Clear Drug-Development Path -- Times 2 The FDA throws a fork in the road for Isis and Genzyme.
The Motley Fool March 15, 2010 Brian Orelli	Clinical Outcomes? Who Needs 'Em. Abbott's TriCor looks good on lab tests, but that's about all.
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
The Motley Fool July 21, 2004 Brian Gorman	Will Cholesterol Drug Pack a Punch? Merck's and Schering-Plough's new combination may receive a lukewarm welcome. In the near term, investors will probably cheer both companies, but in the long run, the companies will be better off it they can come up with something totally original.
BusinessWeek May 27, 2010 Michelle Cortez	Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug.
The Motley Fool April 28, 2011 Brian Orelli	Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval.
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
Chemistry World January 14, 2013 Andrew Turley	Laropiprant recalled Merck & Co has said it is recalling Tredaptive cholesterol tablets in response to trial results that raised safety concerns and the recommendations of a European Medicines Agency safety panel.
The Motley Fool September 2, 2008 Brian Orelli	Cardiologists Hate Vytorin Cardiologists seem cynical about the full presentation of Merck's and Schering-Plough's SEAS data at the European Society of Cardiology.
The Motley Fool December 12, 2007 Brian Orelli	Congress Calls Out Merck and Schering-Plough The House of Representatives wants to know what's taking these pharmaceutical companies so long to release trial data from their ENHANCE clinical trial.
The Motley Fool January 14, 2011 Brian Orelli	Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing.
The Motley Fool July 22, 2008 Brian Orelli	Drug Duo SEAS Disappointment -- Again After numerous disappointments this year, Merck and Schering-Plough continue their string of bad luck.
The Motley Fool January 15, 2010 Brian Orelli	Oops, Sorry About That, Pfizer The FDA says there's no problem with Spiriva after all.
BusinessWeek July 21, 2003 Amy Barrett	A Bare-Knuckle Battle over Cholesterol Drugs If AstraZeneca's Crestor is approved, rivals' stepped-up pitches will focus on safety
The Motley Fool April 21, 2009 Brian Orelli	Schering and Merck: A Match Made in Purgatory Until Merck can show that it's capable of growing sales again, investors should be leery of stepping in, even with the dividend yield pushing 6%.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool December 5, 2008 Brian Orelli	Good Luck in 2010, Merck It's not just one problem for Merck, but a whole series of issues that have turned the company into a heap of stale drugs.
The Motley Fool August 5, 2010 Brian Orelli	Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still.
BusinessWeek March 6, 2006 Amy Barrett	Merck: Out Of The Ivory Tower Merck's pragmatic strategy includes tweaking the vitamin niacin to make it a blockbuster.